摘要 : A risk-adapted treatment strategy is of crucial importance in patients with myelodysplastic syndromes(MDS).Previous risk prognostic scoring systems did not integrate molecular abnormalities.The new IPSS-Molecular(IPSS-M)model,comb... 展开 A risk-adapted treatment strategy is of crucial importance in patients with myelodysplastic syndromes(MDS).Previous risk prognostic scoring systems did not integrate molecular abnormalities.The new IPSS-Molecular(IPSS-M)model,combing genomic profiling with hematologic and cytogenetic parameters,was recently developed to evaluate the associations with leukemia-free survival(LFS),leukemic transformation,and overall survival(OS).However,it has not yet been widely validated in clinics.This study aims to further validate the prognostic power of IPSS-M based on real-world data and to compare the prognostic value of different scoring systems in patients with MDS.IPSS-M Web calculator was used to calculate a tailored IPSS-M score of the enrolled patient(N=255),and the risk category was defined correspondingly.We next compared the IPSS-M prognostic power to that of IPSS,IPSS-R,and WPSS.We found that IPSS-M risk classification was statistically significant for 3-year OS and LFS.Compared with other tools,IPSS-M was superior in sensitivity and accuracy for 3-year OS and LFS.The mapping C-index between IPSS-R and IPSS-M categories resulted in improved discrimination across the OS,but not LFS and leukemic transformation.The result of different treatment options indicated that allogeneic hematopoietic stem cell transplantation(allo-HSCT)can result in a better OS than those without allo-HSCT.In conclusion,IPSS-M was a valuable tool for risk stratification compared with other risk prognostic scoring systems.However,more studies should be conducted to explore the appropriate treatment options for different groups stratified by IPSS-M. 收起